BSD to Showcase MicroThermX® Microwave Ablation System at SIR Meeting - the Largest Forum for Interventional Radiology

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced today that the MicroThermX® Microwave Ablation System (MicroThermX®) will be featured at the Company’s exhibition booth at the 36th annual scientific meeting of the Society of Interventional Radiology (SIR), which will be held in Chicago, Ill., March 26 to March 31, 2011. The SIR meeting is the largest and most comprehensive meeting in the US for minimally invasive interventional radiology/oncology products. Nearly 5,300 physicians, scientists and health professionals from around the world will attend the meeting, reflecting the global impact of the rapidly expanding field of interventional radiology (IR). The SIR meeting theme is "IR Rising: Leading Image-guided Medicine," which was chosen to reflect the ongoing revolution of modern medicine due to the breakthrough treatments provided by the field of interventional radiology. The global market for ablation treatments is expected to reach $2.0 billion.

"The SIR meeting will be used to increase the profile of the Company’s microwave ablation products and to further develop the Company’s association with international key opinion leaders,” stated Steven Smith, VP for Marketing, Sales, and Business Development for BSD. "The focus of this meeting is to showcase high-quality, efficient, minimally invasive medical treatments, which is the perfect forum to highlight the many advantages of the MicroThermX®. BSD plans to use this international meeting to showcase the significant advantages of the MicroThermX® to a large audience of interventional radiology professionals.”

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue and has received marketing clearance from the US FDA. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.


BSD Medical Corporation
Dennis Gauger, 801-972-5555
[email protected]
fax: 801-972-5930

KEYWORDS:   United States  North America  Illinois  Utah

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Oncology  Radiology  General Health